



# Financial Tear Sheet

## Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at [www.incyte.com](http://www.incyte.com).

## Primary IR Contact

Michael Booth, D.Phil.  
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: [mbooth@incyte.com](mailto:mbooth@incyte.com)

## Stock Performance

### INCY (Common)

Exchange	NASDAQ (US Dollar)
Price	<b>\$134.38</b>
Change (%)	<b>▼ 4.03 (2.91%)</b>
Volume	2,366,454
52 Week Low	\$71.75
Market Cap	\$27,517,585,081
Rolling EPS	-0.54
PE Ratio	N/A

Shares Outstanding 204,774,409

Data as of May 26, 2017 4:00 p.m. ET



## Recent Headlines

May 22, 2017

[Incyte to Present at Upcoming Investor Conferences](#)

May 17, 2017

[New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® \(pembrolizumab\)](#)

May 17, 2017

[First Data from Combination of Epacadostat with Opdivo® \(nivolumab\) Will Be Highlighted at ASCO 2017](#)

## Events

Date	Title
06/14/17 10:00 a.m. CT	<b>William Blair Growth Conference</b>
06/15/17 11:00 a.m. UKT	<b>Nasdaq Investor Program</b>

Data provided by Nasdaq. Minimum 15 minutes delayed.